CST logo

#9208 Phospho-p70 S6 Kinase (Ser371) Antibody

CSTコード 包装
希望納入価格 (円)
国内在庫 i
2020年2月21日15時25分 現在
ご登録代理店情報 i
#9208S100 μL67,000
#9208T20 μL39,000
Custom Antibody Sampler Kitの構成品を選択できます。

P70S6K 製品一覧 | #9208 が入っているAntibody Sampler キット一覧

感度分子量 (kDa)抗体の由来貯法
内在性70, 85Rabbit-20℃
種交差性 (社内試験済)
交差する可能性がある種 i


ヒト、マウス、ラット、サル -
9208 の推奨プロトコール i

最適な結果を得るために:Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。



ウェスタンブロッティング (1:1000)


内在性レベルのSer371 がリン酸化されたp70 S6 Kinase を検出します。類似した部位 (Ser394) がリン酸化されたp85 S6 Kinase を検出します。Ser370 がリン酸化されたS6KII βタンパク質も検出する可能性があります。
ヒトのp70 S6 Kinase のSer371 周辺領域 (合成リン酸化ペプチド)

ホモロジー (相同性) 検索をご希望の場合 >>>



※下記の社内データは、すべて9208 の推奨プロトコールで実験した結果です。

Western Blotting

Western Blotting

Western blot analysis of lysates from unsynchronized (U) and nocodazole (N) treated (50ng/ml for 48 hours) HT29 cells using Phospho-p70 S6 Kinase (Ser371) Antibody (B) and p70 S6 Kinase Antibody #9202 (D). Incubation of the nitrocellulose membrane with calf intestinal alkaline phosphatase (CIP) after Western transfer abolishes the phospho-p70 S6 Kinase signal (A), but has no effect on the total p70 S6 kinase signal (C).

Western Blotting

Western Blotting

Western blot analysis of lysates from 293 cells grown in low serum, then treated with 20% serum for 30 minutes alone or after 1 hour preincubation with rapamycin (10nM) #9904 or LY294002 (50uM) #9901, using Phospho-p70 S6 Kinase (Ser371) Antibody (upper) or p70 S6 Kinase Antibody #9202 (lower).


p70 S6 kinase is a mitogen activated Ser/Thr protein kinase that is required for cell growth and G1 cell cycle progression (1,2). p70 S6 kinase phosphorylates the S6 protein of the 40S ribosomal subunit and is involved in translational control of 5' oligopyrimidine tract mRNAs (1). A second isoform, p85 S6 kinase, is derived from the same gene and is identical to p70 S6 kinase except for 23 extra residues at the amino terminus, which encode a nuclear localizing signal (1). Both isoforms lie on a mitogen activated signaling pathway downstream of phosphoinositide-3 kinase (PI-3K) and the target of rapamycin, FRAP/mTOR, a pathway distinct from the Ras/MAP kinase cascade (1). The activity of p70 S6 kinase is controlled by multiple phosphorylation events located within the catalytic, linker and pseudosubstrate domains (1). Phosphorylation of Thr229 in the catalytic domain and Thr389 in the linker domain are most critical for kinase function (1). Phosphorylation of Thr389, however, most closely correlates with p70 kinase activity in vivo (3). Prior phosphorylation of Thr389 is required for the action of phosphoinositide 3-dependent protein kinase 1 (PDK1) on Thr229 (4,5). Phosphorylation of this site is stimulated by growth factors such as insulin, EGF and FGF, as well as by serum and some G-protein-coupled receptor ligands, and is blocked by wortmannin, LY294002 (PI-3K inhibitor) and rapamycin (FRAP/mTOR inhibitor) (1,6,7). Ser411, Thr421 and Ser424 lie within a Ser-Pro-rich region located in the pseudosubstrate region (1). Phosphorylation at these sites is thought to activate p70 S6 kinase via relief of pseudosubstrate suppression (1,2). Another LY294002 and rapamycin sensitive phosphorylation site, Ser371, is an in vitro substrate for mTOR and correlates well with the activity of a partially rapamycin resistant mutant p70 S6 kinase (8).

12630   SignalFire™ Plus ECL Reagent
12757   SignalFire™ Elite ECL Reagent
2708   p70 S6 Kinase (49D7) Rabbit mAb
6883   SignalFire™ ECL Reagent
7074   Anti-rabbit IgG, HRP-linked Antibody
7727   Biotinylated Protein Ladder Detection Pack
9202   p70 S6 Kinase Antibody
9204   Phospho-p70 S6 Kinase (Thr421/Ser424) Antibody
9205   Phospho-p70 S6 Kinase (Thr389) Antibody
9206   Phospho-p70 S6 Kinase (Thr389) (1A5) Mouse mAb
9234   Phospho-p70 S6 Kinase (Thr389) (108D2) Rabbit mAb
9862   mTOR Substrates Antibody Sampler Kit
9864   mTOR Regulation Antibody Sampler Kit
9964   mTOR Pathway Antibody Sampler Kit

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.


Phospho-p70 S6 Kinase (Ser371) Antibody

Metabolic Reprogramming in Disease